Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11848105 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBMAPTEPHX2 | |
| SCHEMBL28810775 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBMAPTEPHX2 | |
| SCHEMBL19474878 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBMAPTEPHX2 | |
| SCHEMBL844467 | 0.98 | ALDH1A1 (0.54) | ALDH1A1TSHRTHRBMAPTPPM1B | |
| SCHEMBL4574844 | 0.93 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBMAPTEPHX2 | |
| SCHEMBL4206502 | 0.92 | ALDH1A1 (0.48) | ALDH1A1TSHRTHRBMAPTEPHX2 | |
| SCHEMBL10550382 | 0.91 | ALDH1A1 (0.51) | ALDH1A1TSHRTHRBMAPTSMN1; SMN2 | |
| SCHEMBL844829 | 0.90 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBMAPTSMN1; SMN2 | |
| SCHEMBL3972242 | 0.89 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPTPPM1BPTPN1 | |
| SCHEMBL879299 | 0.89 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPTPPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084173-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERITY OF ALBERTA (CA) | 2006-08-01 | — | — | US | claimed |
| US-20030191182-A1 | Compounds that stimulate glucose utilization and methods of use | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-10-09 | — | — | US | claimed |
| US-20030191182-A1 | Compounds that stimulate glucose utilization and methods of use | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191182-A1 | Compounds that stimulate glucose utilization and methods of use | GPR119, SLC2A3, CYCS | ALDH1A1 2045/4885TSHR 732/4885THRB 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.